{"date":"2026-02-21","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6919-2026-02-21-1756-15c4a2c","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-02-21","time":"17:56:20","subject":"本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之亞太二期臨床試驗CBL-0206，已於2/17完成澳洲主管機關HREC申請","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-02-21 17:56，「本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之亞太二期臨床試驗CBL-0206，已於2/17完成澳洲主管機關HRE」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}